Medical Marijuana Inc (OTCMKTS:MJNA) has released a letter to the investors explaining the operational, financial results, and upcoming objectives.

Highlights

Medical Marijuana has summarized its three initiatives and one plant approach to benefit from the growth of CBD and Industrial hemp by becoming a leader in R&D of CBD based therapeutics, a global house of the brands, and a supplier of good quality cannabidiol raw materials on the global arena.

It has provided guidance on financial performance for the rest of the year. Medical Marijuana is on track to achieve the adjusted EBITDA goal of $5.1 million annually. The company has provided information on recent financial results and financial progress that include a surge in gross profit, robust sales, and a reduction in operational expenditure.

Provided outcome of the CEO D. Stuart Titus’s successful testimony before the FDA after the agency gave the nod to testify. It is the only company to find a place for the cannabidiol products in Prescriber’s Digital Reference.

To provide transparency and give communications at the right time to the investors, Medical Marijuana has made improvements to the financial and business strategies. Medical Marijuana has appointed Dr. Levan Darjania to head R&D. Dr. Levan ensures its products withstand the climate extremes and challenges in the overseas.

CEO said the company changed the business strategy to stay ahead of the trends and capitalize on the growing CBD industry by 2025 through planning. Medical Marijuana has posted excellent growth in the past year and delivered solid growth so far this year. The company expects to post the same momentum to post excellent results going forward.

Participates in a clinical trial

CBD based toothpaste and mouth wash products from oral care line of Axim Biotechnologies Inc (OTCMKTS:AXIM), an investment company of Medical Marijuana, are included in the clinical trials registration through New Zealand and Australia Clinical Trial Registry. Dr. Stuart said additional research would benefit the CBD industry. Medical Marijuana will participate in the clinical trial of these oral care products.

Impression Healthcare Limited will conduct the clinical trial on CBD based mouth wash and toothpaste involving 40 people, who are suffering from gum disease and gingivitis, in 30 days and monitors for overall gum health and gum inflammation.